Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure: Prospective Randomized Trial (DETAIL-CMIV)

NCT05816733 is registered in ClinicalTrials.gov with Kun Hua as lead sponsor.

NCT NCT05816733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05816733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure: Prospective Randomized Trial (DETAIL-CMIV)
Lead sponsor
Kun Hua
Phase
Phase 4
Overall status
Unknown status
Start date
September 1, 2023
Completion date
August 7, 2024
Enrollment
348 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, atrial fibrillation recurrence, cox maze iv, patients with or without heart failure and diabetes